Urinary and serum pteridines in liver diseases

Pteridines

Volumn 7, Issue 4, 1996, Pages 160-165

  Mazda, Toshio ^a   Iino, Teruhiko ^b   Tsusué, Motoo ^c  

^a Japanese Red Cross Society   (Japan)

^b NIHON UNIVERSITY   (Japan)

^c KITASATO UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

NEOPTERIN; PTERIDINE DERIVATIVE; XANTHOPTERIN;

CHRONIC ACTIVE HEPATITIS; EXCRETION; FATTY LIVER; HEPATITIS; HUMAN; LIVER DISEASE; LIVER INJURY; PRIORITY JOURNAL; REVIEW; SCREENING; URINALYSIS;

EID: 0030480112     PISSN: 09334807     EISSN: 21954720     Source Type: Journal    
DOI: 10.1515/pteridines.1996.7.4.160     Document Type: Review

References (44)

1. Matsubara M, Tsusué M, Akino M. Occurrence of two different enzymes in the silkworm, Bombyx mori, to reduce folate and sepiapterin. Nature 1963; 199: 908-910.
2. Ohashi M, Tsusué M, Yoshitake S, Sakate S. Epidermal pigments affecting the larval coloration of the silkworm, Bombyx mori. J. Sericult Sci. Ipn. 1983; 52: 498-502.
3. Ohashi M, Tsusué M, Kiguchi K. Juvenile hormone control of larval coloration in the silkworm, Bombyx mori: characterization and determination epidermal brown color induced by the hormone. Insect Biochem. 1983; 13: 123-127.
4. Nakakoshi M, Masada M, Tsusué M. The nature of the seasonal color dimorphism in the scorpion fly, Panorpa Japonica Thunberg. Insect Biochem. 1984; 14: 615-618.
5. Tsusué M, Kuroda S, Sawada H. Localization of sepiapterin deaminase and pteridines in the granules in epidermal cells of the silkworm Bombyx mori. Pteridines 1990; 2: 175-182.
6. Sawada H, Tsusué M, Yamamoto T, Sakurai S. Occurrence of xanthommatine containing pigment granules in the epidermal cells of the silkworm Bombyx mori. Insect Biochem. 1990; 20: 785-792.
7. Kaufman S, Fisher DB. Pterinrequiring aromatic amino acid hydroxylases. In Hayashi O, ed. Molecular Mechanisms of Oxygen Activation. New York, Academic Press. 1974; 285-369.
8. Kaufman S, Holtzman NA, Milstien S, Butler IJ, Krumholz A. Phenylketonuria due to a deficiency of dihydropteridine reductase. N. Engl. J. Med. 1975; 293: 785-790.
9. Kaufman S, Berlow S, Summer GK, et al. Hyperphenylalaninemia due to a deficiency of biopterin. N. Engl. J. Med. 1978; 299: 673-679.
10. Fuchs D, Hausen A, Reibnegger G, Werner ER, Dierich MP, Wachter H. Neopterin as a marker for activated cell-mediated immunity: application in HIV infection. Immunol. Today. 1988; 9: 150-155.
11. Hausen A, Fuchs D, Reibnegger G, Werner ER, Wachter H. Neopterin in clinical use. Pteridines 1989; 1: 3-10.
12. Fahey JL, Taylor JMG, Detels R et al. The prognostic value of cellular and serologic markers in infection with human immunodeficiency virus type 1. N. Eng. J. Med. 1990; 322: 166-172.
13. Prior C, Fuchs D, Hausen A et al. Potential of urinary neopterin excretion in differentiating chronic non-A, non-B hepatitis from fatty liver. Lancet 1987; ii: 1235-1237.
14. Japanese Red Cross Non-A, Non-B Hepatitis Research Group: Effect of screening for hepatitis C virus antibody and hepatitis B virus core antibody on incidence of post-transfusion hepatitis. Lancet 1991; 338: 1040-1041.
15. Mazda T, Nakata K, Ota K, Kaminuma Y, Katayama T. The effect of prior transfusion history on blood donor anti-hepatitis C virus antibody. Southeast Asian J Trop Med Public Health 1993; 24 (Suppl 1): 183-186.
16. Nishioka K. Transfusion-transmitted HBV and HCV. Vox Sang 1996; 70 (Suppl 3): 4-8.
17. Fukushima K, Eto I, Mayumi T, Richter W, Goodson S, Shiota T. Biosynthesis of pterins in mammalian systems. In: Pfleiderer W, ed. Chemistry and Biology of Pteridines. Berlin-New York: Walter de Gruyter, 1975; 247-263.
18. Fukushima T, Shiota T. Pterins in human urine. J. Biol. Chem. 1972; 247: 4549-4556.
19. Rokos H, Rokos K, Frisius H, Kirstaedter H-J. Altered urinary excretion of pteridines in neoplastic disease. Determination of biopterin, neopterin, xanthopterin, and pterin. Clin. Chim. Acta 1980; 105: 275-286.
20. Stea B, Halpern RM, Halpern BC, Smith RA. Urinary excretion levels of unconjugated pterins in cancer patients and normal individuals. Clin. Chim. Acta 1981; 113: 231-242.
21. Yoshioka S, Masada M, Yoshida T, Inoue K, Mizokami T, Akino M. Synthesis of biopterin from dihydroneopterin triphosphate by rat tissues. Biochim. Biophys. Acta 1983; 756: 279-285.
22. Fuchs D, Milstien S, Kramer A et al: Urinary neopterin concentrations vs total neopterins for clinical utility. Clin. Chem. 1989; 35: 2305-2307.
23. Plesner P, Kalckar HM. Enzymic micro determinations of uric acid, hypoxanthine, xanthine, adenine, and xanthopterine by ultraviolet spectrophotometry. Methods of Biochemical Analysis 1956; 3: 97-110.
24. Mazda T, Ogasawara K, Fukuda A, Gyure WL, Tsusué M. Urinary xanthopterin and derivatives as indicators of liver disease. In: Curtius HC, Ghisla S, Blau N. ed. Chemistry and Biology of Pteridines 1989. Berlin-New York: Walter de Gruyter, 1990; 579-582.
25. Fukuda A, Mazda T, Gyure WL et al. A comparative study of urinary xanthopterin and neopterin in liver diseases. Eur. J. Clin. Chem. Clin. Biochem. 1993; 31: 129-134.
26. Choo Q-L, Kuo G, Weiner AJ, Overby LR, Bradley DW, Houghton H. Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science 1989; 244: 359-362.
27. Kuo G, Choo Q-L, Alter HJ et al. An assay for circulating antibodies to a major etiologic virus of human non-A, non-B hepatitis. Science 1989; 244: 362-364.
28. Mazda T, Nojiri N, Kimura H, Iino T, Ohbayashi A. Plasma neopterin in hepatitis C virus antibody-positive and -negative donors with elevated alanine aminotransferase activity. Pteridines 1994; 5: 111-113.
29. Iino T, Watanabe H, Gyure WL, Mazda T, Mieno H, Tsusué M. An example of the detection of an esophageak carcinoma in its very early stage by urinary xanthopterin determination. In: Ayling JE et al. eds. Chemistry and Biology of Pteridines. New York: Plenum Press, 1993; 243-246.
30. Wachter H, Hausen A, Graβmayr K: Erhoete. Aussheidung von Neopterin im Harn von Patienten mit malignen Tumoren und mit Viruserkrankungen. Hoppe-Seyler's Z Physiol. Chem. 1979; 360: 1957-1960.
31. Fuchs D, Hausen A, Huber C, et al. Pteridinausscheidung als Marker fr alloantigen-induzierte Lymphozytenproliferation. Hoppe-Seyler's Z. Physiol. Chem. 1982; 363: 661-664.
32. Margreiter R, Fuchs D, Hausen A, et al. Neopterin as a new biochemical marker for diagnosis of allograft rejection. Experience based upon evaluation of 100 consecutive cases. Transplantation 1983; 36: 650-653.
33. Niederwieser D, Huber C, Gratwohl A, et al. Neopterin as a new biochemical marker in the clinical monitoring of bone marrow transplant recipients. Transplantation 1984; 38: 497-500.
34. Reibnegger G, Aichberger C, Fuchs D, et al. Post-transplant neopterin excretion in renal allograft recipients - a reliable diagnostic aid for acute rejection and a predictive marker of long-term graft survival. Transplantation 1991; 52: 58-63.
35. Zangerle R, Schönitzer D, Fuchs D, Most J, Dierich MP, Wachter H. Reducing HIV transmission by seronegative blood (letter). Lancet 1992; 339: 130-131.
36. Fuchs D, Hausen A, Reibnegger G, et al. Urinary neopterin in the diagnosis of acquired immune deficiency syndrome. Eur. J. Clin. Microbiol. 1984; 3: 70-71.
37. Abita JP, Cost H, Milstien S, Kaufman S, Saimot G. Urinary neopterin and biopterin levels in patients with AIDS and AIDS - related complex (letter). Lancet ii: 51-52, 1985.
38. Fuchs D, Spira TJ, Hausen A, et al. Neopterin as predictive marker for disease progression in human immunodeficiency virus type 1 infection. Clin Chem 1989; 35: 1746-1749.
39. Fuber C, Batchelor JR, Fuchs D et al. Immune response-associated production of neopterin. Release from macrophages primarily under control of interferon gamma. J. Exp. Med. 1984; 160: 310-316.
40. Schoedon G, Troppmair J, Fontana A, Huber C, Curtius H-C, Niederwieser A. Biosynthesis and metabolism of pterins in peripheral blood mononuclearcells and leukemia lines of man and mouse. Eur. J. Biochem. 1987; 166: 303-310.
41. Werner-Felmayer G, Werner ER, Fuchs D, Hausen A, Reibnegger G, Wachter H. Neopterin formation and tryptophan degradation by a human myelomonocytic cell line (THP-1) upon cytokine treatment. Cancer Res. 1990; 50: 2863-2867.
42. The Japanese Red Cross Society Post Transfusion Hepatitis Research Group Reports 1993-1995. Tokyo: Japanese Red Cross Society, 1996; 7-14 (in Japanese).
43. Simons JN, Leary TP, Dawson GJ, et al. Isolation of novel virus-like sequences associated with human hepatitis. Nature Med 1995; 1: 564-569.
44. Linnen J, Wages J, ZhangKeck ZY, et al. Molecular cloning and disease association of hepatitis G virus: a transfusion-transmissible agent. Science 1996; 271: 505-508.